Rayno DX and Tools: Update on metrics and performance
Pure Play Clinical Diagnostic Companies Here is data on our clinical diagnostics universe including Q3 revenues and earnings. New buy is Cepheid (CPHD) under $32. Sequenom is up 22% over 5 days Turn-around plays are Alere (ALR), Qiagen(QGEN) and Response Genetics (RGDX) Four companies on our...
Rayno Life Science Mid-day Movers: AMRI, ASTX, CPHD, ILMN, REGN
Markets Are Back To Fretting About Fiscal Cliff Bernanke scolded Congress on the fiscal cliff and markets turned down. Despite a lackluster market down about 0.3% there is a lot of green in biotech. Among the winners in the Rayno Life Science universe are: Albany Molecular (AMRI $4.21) broke...
Stocks Turn Green in Major Reversal: Biotechs In Stealth Rally
Politicians Offer Hope Of Deal and Are Looking For Common Ground Boehner puts revenue on the table passing off next move to DEMS for cuts. Reid says he will not wait till end of the year to cut a deal. S&P goes from down 10 to up 4. NASDAQ up 7. AAPL rallies from low of $505.75 to $523....
Update On Emerging Biomarker Diagnostics: BG Medicine, Response Genetics, Vermillion
Response Genetics (RGDX) Offers Good Value and Is Positioned For Revenue Growth In April we compared two emerging companies focused in biomarker diagnostics, BG Medicine, Inc. and Vermillion, Inc. offering a challenge to readers as to which stock would be the winner in 2012. Both companies...
Raygent Biopharmaceutical Portfolio: Celgene (CELG) and Gilead (GILD) Ignite Rally
A languishing biotech sector rallied today with clinical news with Hepatitis C (HCV) drugs. The Rayno Biopharma Portfolio was up 2.4% led by Gilead Sciences (GILD) up 11.5%, Regeneron (REGN) up 3.3% and ViroPharma (VPHM) up 3.2%. Gilead shares were up $7.50 on favorable Phase 2 results with...